- Biotech on the Web - https://biotechontheweb.com -

Bausch Health And BHVI Announce Exclusive Global Licensing Agreement For Myopia Control Contact Lens

Share:
[1] [2] [3] [4]

Second Exclusive License Strengthens Bausch + Lomb’s Global Research Focus on Myopia

SYDNEY and LAVAL, QC, Oct. 15, 2020 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and Bausch + Lomb, its leading global eye health business, along with BHVI, an Australian not-for-profit organization with an international focus on vision research, announced today that an affiliate of Bausch Health has acquired an exclusive license for a myopia control contact lens design developed by BHVI. Bausch + Lomb will pair BHVI’s novel contact lens design with its leading contact lens technologies to develop potential contact lens treatments designed to slow the progression of myopia in children.

Myopia, also known as nearsightedness, is among the most common ocular disorders worldwide and is a leading cause of visual impairment in children.1 Studies have predicted that the global prevalence of myopia will rise from 28% of the world’s population, or two billion people, in 2010 to 50% of the world’s population, or five billion people, in 2050.2 In fact, uncorrected myopia is a leading cause of blindness worldwide.

MORE…

Author: Canan Schuman, PharmD/PhD [5]

Canan Schumann is Chief Editor for Axxiem and for Axxiem's blog "BiotechOntheWeb". When not writing for Axxiem, Canan works as a Clinical Research Scientist II at the Research and Development Department at Molecular Testing Labs, developing endpoint assays for the detection of infectious disease and cancer. Canan currently resides in Portland, Oregon, where he received his Honors Bachelor of Science (HBS), Doctor of Pharmacy (PharmD.), and his Doctor of Philosophy (Ph.D.) in Biopharmaceutics at Oregon State University.